Having shown that α-synuclein prions in MSA patient samples exhibit a number of properties consistent with PrP prions in CJD patients, we sought to establish and define a rigorous transgenic mouse model of α-synuclein prion propagation to support ongoing drug discovery efforts for MSA therapeutics. Here, SNCA is linked to Creutzfeldt Jacob disease.